J&J Units Target Impax Over Generic Concerta

Law360, New York (November 30, 2010, 6:19 PM EST) -- Two Johnson & Johnson units have fired off a suit seeking to block Impax Laboratories Inc. from launching a generic version of attention deficit disorder treatment Concerta.

Impax confirmed Monday that Alza Corp. and Ortho-McNeil-Janssen Pharmaceuticals Inc. filed a complaint in the U.S. District Court for the District of Delaware on Nov. 24 in an effort to stop Impax and partner Teva Pharmaceutical Industries Ltd. from gaining approval by the U.S. Food and Drug Administration to make and sell a generic version of extended-release 54 mg...
To view the full article, register now.